Welcome to LookChem.com Sign In|Join Free
  • or

211915-06-9

Post Buying Request

211915-06-9 Suppliers

Recommended suppliersmore

Product FOB Price Min.Order Supply Ability Supplier
Dabigatran etexilate
Cas No: 211915-06-9
USD $ 3.0-3.0 / Kilogram 1 Kilogram 1-100 Metric Ton/Month Hangzhou Dayangchem Co., Ltd. Contact Supplier
Factory supply Dabigatran etexilate Cas 211915-06-9 with high quality and favorable price
Cas No: 211915-06-9
USD $ 2500.0-2727.0 / Kilogram 1 Kilogram 1 Metric Ton/Year Wuhan Fortuna Chemical Co.,Ltd Contact Supplier
High quality Dabigatran Etexilate supplier in China
Cas No: 211915-06-9
No Data No Data No Data Simagchem Corporation Contact Supplier
Dabigatran etexilate
Cas No: 211915-06-9
No Data No Data No Data Chemwill Asia Co., Ltd. Contact Supplier
Dabigatran etexilate
Cas No: 211915-06-9
No Data No Data 5 Metric Ton/Day Shanghai SE Pharm Co., Ltd Contact Supplier
Hot sales, Dabigatran etexilate
Cas No: 211915-06-9
USD $ 1.0-1.0 / Kilogram 1 Kilogram 10 Metric Ton/Month Hebei yanxi chemical co.,LTD. Contact Supplier
Dabigatran etexilate Supplier
Cas No: 211915-06-9
No Data 100 Gram 100 Kilogram/Week HENAN SUNLAKE ENTERPRISE CORPORATION Contact Supplier
211915-06-9 Dabigatran Etexilate (free base)
Cas No: 211915-06-9
USD $ 8900.0-8900.0 / Gram 1 Gram 200 Gram/Day Henan Tianfu Chemical Co., Ltd. Contact Supplier
Pradaxa powder supplier/suppliers manufacturer factory
Cas No: 211915-06-9
No Data No Data 1000 Metric Ton/Month Crovell Biotech (Hebei) Co., Ltd. Contact Supplier
Pharmaceutical Intermediate CAS 211915-06-9 Dabigatran etexilate powder supplier
Cas No: 211915-06-9
No Data 10 Gram 10 Metric Ton/Week Hubei XinRunde Chemical Co., Ltd Contact Supplier

211915-06-9 Usage

Warnings and Precautions

1. Dabigatran is not to be used by patients with severe kidney damage (CrCl<30ml/min).
2. Patients with high bleeding risk should also not use Dabigatran.
3. Patients must be tested and monitored for signs of lack of bleeding or anemia; if there is severe bleeding, cease use of Dabigatran and identify the bleeding area.
4. Dabigatran is not suitable for patients with significant manifestations of rheumatic valvar heart disease or patients with artificial heart valves.

Uses

BIBR-1048 (Dabigatran) is an anticoagulant from the class of the direct thrombin inhibitors. It is being studied for various clinical indications and in many cases it offers an alternative to warfarin as the preferred orally administered blood thinner sin

Clinical Research

Compared to the control group treated with Warfarin, Dabigatran can significantly decrease the risk of stroke and embolic disease (including hemorrhagic stroke), greatly reduce the occurrence of bleeding (including fatal bleeding and intracranial hemorrhage), and greatly lower vascular mortality rate. Dabigatran provides effective and stable anticoagulant effects and does not require constant monitoring of anticoagulant functions or dosage adjustments.

Mechanisms of Action

It achieves anticoagulant effects through specific and selective inhibition of blood enzymes (free or bound). After oral ingestion and absorption through the digestive system, Dabigatran turns into Dabiga groups that have the direct anticoagulant abilities. By binding to thrombin in fibrin specific binding sites, Dabigatran stops fibrinogen from cleaving into fibrin, thus interrupting the blood clotting network and consequently thrombosis. Dabiga groups can also dissociate from the fibrin-thrombin coagulate and have an anticoagulating effect. Different from vitamin K antagonists, which affect different coagulants, Dabigatran can provide effective, predictable and stable anticoagulant effects. It will also have minimal reactions to other drugs or food, and does not require frequent monitoring or dosage adjustment.

Indications and Usage

Dabigatran is the newest generation of oral anticoagulant drugs – direct thrombin inhibitors (DTIs), belonging to non-peptide thrombin inhibitors and instead specifically and selectively blocks the thrombin activity (free or bound) to prevent coagulation. Dabigatran targets the preventative and clinical treatment needs of acute and chronic thromboembolic disease.

Definition

ChEBI: An aromatic amide obtained by formal condensation of the carboxy group of 2-{[(4-{N'-[(hexyloxy)carbonyl]carbamimidoyl}phenyl)amino]methyl}-1-methyl-1H-benzimidazole-5-carboxylic acid with the secondary amino group of thyl N-pyridin-2-yl-beta-alaninate. A prodrug for dabigatran, a thrombin inhibitor and anticoagulant which is used for the prevention of stroke and systemic embolism.
InChI:InChI=1/C34H41N7O5/c1-4-6-7-10-21-46-34(44)39-32(35)24-12-15-26(16-13-24)37-23-30-38-27-22-25(14-17-28(27)40(30)3)33(43)41(20-18-31(42)45-5-2)29-11-8-9-19-36-29/h8-9,11-17,19,22,37H,4-7,10,18,20-21,23H2,1-3H3,(H2,35,39,44)

211915-06-9SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 14, 2017

Revision Date: Aug 14, 2017

1.Identification

1.1 GHS Product identifier

Product name dabigatran etexilate

1.2 Other means of identification

Product number -
Other names phenol red sodium salt

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:211915-06-9 SDS

Please post your buying leads,so that our qualified suppliers will soon contact you!

*Required Fields